Literature DB >> 12150820

Alternative and aberrant splicing of MDM2 mRNA in human cancer.

Frank Bartel1, Helge Taubert, Linda C Harris.   

Abstract

MDM2 has been characterized as a protein that binds to and facilitates degradation of the tumor suppressor p53. Interestingly, more than 40 different splice variants of MDM2 transcripts have been identified both in tumors and normal tissues, and the majority of these variants do not contain sequence encoding the p53 binding site. This review describes the different splice forms, the tissues in which they have been identified, and their association with tumor progression and prognosis. In addition, we discuss the potential functions of these variants and how they interact with full-length MDM2 protein.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12150820     DOI: 10.1016/s1535-6108(02)00091-0

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  81 in total

1.  Cotranscriptional exon skipping in the genotoxic stress response.

Authors:  Martin Dutertre; Gabriel Sanchez; Marie-Cécile De Cian; Jérôme Barbier; Etienne Dardenne; Lise Gratadou; Gwendal Dujardin; Catherine Le Jossic-Corcos; Laurent Corcos; Didier Auboeuf
Journal:  Nat Struct Mol Biol       Date:  2010-10-24       Impact factor: 15.369

Review 2.  Emerging roles of BRCA1 alternative splicing.

Authors:  T I Orban; E Olah
Journal:  Mol Pathol       Date:  2003-08

3.  SON is a spliceosome-associated factor required for mitotic progression.

Authors:  Michael S Y Huen; Shirley M H Sy; Ka Man Leung; Yick-Pang Ching; George L Tipoe; Cornelia Man; Shuo Dong; Junjie Chen
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

4.  Differentially Expressed mRNA Targets of Differentially Expressed miRNAs Predict Changes in the TP53 Axis and Carcinogenesis-Related Pathways in Human Keratinocytes Chronically Exposed to Arsenic.

Authors:  Laila Al-Eryani; Sabine Waigel; Ashish Tyagi; Jana Peremarti; Samantha F Jenkins; Chendil Damodaran; J C States
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

5.  Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.

Authors:  Mikael S Lindström; Aiwen Jin; Chad Deisenroth; Gabrielle White Wolf; Yanping Zhang
Journal:  Mol Cell Biol       Date:  2006-11-20       Impact factor: 4.272

6.  Structural genomics analysis of alternative splicing and application to isoform structure modeling.

Authors:  Peng Wang; Bo Yan; Jun-Tao Guo; Chindo Hicks; Ying Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-14       Impact factor: 11.205

Review 7.  Genomic alterations in Hodgkin's lymphoma.

Authors:  Marc A Weniger; Thomas F E Barth; Peter Möller
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

8.  Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains.

Authors:  Chad A Corcoran; JoAnne Montalbano; Hong Sun; Qin He; Ying Huang; M Saeed Sheikh
Journal:  J Biol Chem       Date:  2009-05-29       Impact factor: 5.157

9.  A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.

Authors:  Sophia Adamia; Benjamin Haibe-Kains; Patrick M Pilarski; Michal Bar-Natan; Samuel Pevzner; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; John Burke; Ilene Galinsky; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Richard Stone; James D Griffin
Journal:  Clin Cancer Res       Date:  2013-11-27       Impact factor: 12.531

10.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.